MedTrace Logo

Intratumoral PH-762 for Cutaneous Carcinoma

NCT06014086 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-02-11

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the safety and tolerability of intratumoral injections of PH-762 in squamous cell carcinoma, melanoma, or Merkel cell carcinomas of the skin, to understand what the body does to the PH-762, and to observe how the tumor responds to the drug. Participants will receive four injections of PH-762 at weekly intervals, into a single tumor, followed by surgical removal of the tumor approximately two weeks later.

Conditions

  • Squamous Cell Carcinoma of the Skin
  • Malignant Melanoma of Skin
  • Merkel Cell Carcinoma of Skin

Interventions

DRUG

PH-762

PH-762 is a potent RNAi molecule targeting PD-1.

Sponsors & Collaborators

  • Prosoft Clinical

    collaborator OTHER

  • Phio Pharmaceuticals Inc.

    lead INDUSTRY

Principal Investigators

  • Linda Mahoney · Phio Pharmaceuticals Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-07
Primary Completion
2025-12-29
Completion
2026-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06014086 on ClinicalTrials.gov